Results 21 to 30 of about 303,632 (262)
Cancer, 2022 Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease‐progression is unknown.
A. Álvarez-Larrán +29 more
semanticscholar +1 more source
Genetic Background of Polycythemia Vera
Genes, 2022 Polycythemia vera belongs to myeloproliferative neoplasms, essentially by affecting the erythroblastic lineage. JAK2 alterations have emerged as major driver mutations triggering PV-phenotype with the V617F mutation detected in nearly 98% of cases.
Mathilde Regimbeau +3 more
semanticscholar +1 more source
Journal of Agromedicine and Medical Sciences (AMS), 2023 Polycythemia vera happened in people around 40-60 years old and mostly men. The criteria are total red blood cells ≥36 mL/kg in males, thrombocytosis, leukocytosis, and JAK2 mutation.
I Gusti Ayu Ratna Dewi +2 more
doaj +1 more source
Journal of Hematology & Oncology, 2021 In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose was significantly lower in the ten ...
F. Pimpinelli +18 more
semanticscholar +1 more source
Anesthetic management of a patient with polycythemia vera undergoing emergency repair of a type-A aortic dissection and concomitant coronary artery bypass grafting: a case report [PDF]
Korean Journal of Anesthesiology, 2015 Polycythemia vera is a chronic progressive myeloproliferative disease characterized by increased circulating red blood cells, and the hyperviscosity of the blood can lead to an increased risk of arterial thrombosis.
Hyeongwoo Im +4 more
doaj +1 more source
Aberrant expression of microRNA in polycythemia vera
Haematologica, 2008 Background Polycythemia vera is a clonal hematopoietic stem cell disorder in which the JAK2 V617F mutation is observed in >95% of patients, but an as yet unidentified process appears to initiate the clonal expansion of hematopoiesis.
Hana Bruchova +2 more
doaj +1 more source
Extent of hematopoietic involvement by TET2 mutations in JAK2V617F polycythemia vera
Haematologica, 2011 TET2 mutations are found in polycythemia vera and it was initially reported that there is a greater TET2 mutational burden than JAK2V617F in polycythemia vera stem cells and that TET2 mutations precede JAK2V617F.
Sabina I. Swierczek +7 more
doaj +1 more source
Haematologica, 2008 We analyzed the effect of hydroxyurea on the JAK2V617F allelic ratio (%JAK2V617F), measured in purified blood granulocytes, of patients with polycythemia vera and essential thrombocythemia.
François Girodon +8 more
doaj +1 more source
Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study [PDF]
, 2019 Splenomegaly is one of the major clinical manifestations of primary myelofibrosis and is common also in other chronic Philadelphia-negative myeloproliferative neoplasms, causing symptoms and signs and affecting quality of life of patients diagnosed with ...
Accurso V. +8 more
core +1 more source
American journal of hematology/oncology, 2020 Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) respectively characterized by clonal erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding ...
A. Tefferi, T. Barbui
semanticscholar +1 more source